Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023 Oct 5, 2023 08:00AM
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc. Sep 21, 2023 08:58AM
Paratek Pharmaceuticals (PRTK) Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S Sep 18, 2023 09:39AM
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/S Sep 18, 2023 09:37AM
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/S Sep 12, 2023 07:30AM
View Older Stories

Sep 7, 2023 03:34PM Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings
Aug 3, 2023 08:00AM Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue of $40.0 Million
Aug 2, 2023 05:36PM Paratek Pharmaceuticals Files Definitive Proxy Statement and Letter to Stockholders in Connection with Acquisition by Gurnet Point Capital and Novo Holdings
Jul 10, 2023 08:03AM Paratek Pharmaceuticals (PRTK) Announces Modification of BARDA Contract to Advance the Development of NUZYRA for Post-Exposure Prophylaxis and Treatment of Pulmonary Anthrax
Jul 10, 2023 08:00AM Paratek Pharmaceuticals Announces Modification of BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
Jun 27, 2023 12:01PM Paratek Pharmaceuticals (PRTK) Acknowledges Receipt of NexPoint Letter
Jun 27, 2023 12:01PM Paratek Pharmaceuticals Acknowledges Receipt of NexPoint Letter
Jun 27, 2023 08:05AM Paratek Pharmaceuticals (PRTK) Announces EMA COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA for Treatment of Nontuberculous Mycobacterial Lung Disease
Jun 27, 2023 08:00AM European Medicines Agency COMP Recommends Positive Opinion on Orphan Medicinal Product Designation for NUZYRA® (omadacycline) for Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
Jun 12, 2023 08:00AM Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at ASM Microbe 2023
Jun 6, 2023 09:06AM Paratek Pharmaceuticals (PRTK) to be Acquired by Gurnet Point Capital and Novo Holdings
Jun 6, 2023 09:05AM Paratek Pharmaceuticals to be Acquired by Gurnet Point Capital and Novo Holdings
May 9, 2023 04:05PM Paratek Pharmaceuticals Announces First Quarter 2023 Revenue of $31.2 Million
May 1, 2023 08:30AM Paratek Pharmaceuticals to Report Financial Results for First Quarter 2023 on May 9
Apr 10, 2023 07:30AM Paratek Pharmaceuticals (PRTK) Presents New Data from NUZYRA
Apr 10, 2023 07:30AM Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMI
Mar 16, 2023 07:30AM Paratek Pharmaceuticals Announces Full-Year 2022 Revenue of $160.3 Million
Mar 8, 2023 08:30AM Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 16
Mar 1, 2023 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Feb 1, 2023 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jan 18, 2023 07:01AM Paratek Pharmaceuticals (PRTK) Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
Jan 18, 2023 07:00AM Paratek Pharmaceuticals Announces Inclusion of NUZYRA® (omadacycline) in China’s National Reimbursement Drug List (NRDL)
Jan 5, 2023 08:03AM Paratek Pharmaceuticals (PRTK) Receives $36.4M Milestone Payment Associated with the Second Procurement of NUZYRA
Jan 5, 2023 08:00AM Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Dec 20, 2022 07:32AM Paratek Pharmaceuticals (PRTK) Appoints Jeffrey Stein to its Board
Dec 20, 2022 07:30AM Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Board
Dec 19, 2022 07:31AM Paratek Pharmaceuticals (PRTK) Reports Positive Top Line Data, Acceptance of the Second Procurement of NUZYRA under BARDA Project BioShield
Dec 19, 2022 07:30AM Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARD
Dec 1, 2022 05:45PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 21, 2022 04:05PM Paratek Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference
Nov 3, 2022 04:05PM Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million
Nov 1, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Nov 1, 2022 08:00AM Paratek Pharmaceuticals to Present at the Credit Suisse 31st Annual Healthcare Conference
Oct 31, 2022 08:00AM Paratek Announces First Milestone Towards Creating a U.S. Manufacturing Supply Chain for NUZYRA® (omadacycline) under BARDA Project BioShield Contract
Oct 25, 2022 08:00AM Paratek Pharmaceuticals to Report Third-Quarter 2022 Financial Results on Nov. 3
Oct 13, 2022 04:05PM Paratek Pharmaceuticals (PRTK) Presents New NUZYRA Data
Oct 13, 2022 04:05PM Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2022
Oct 3, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 26, 2022 08:30AM Paratek Pharmaceuticals to Host Investor Update on the Global Opportunity in Non-Tuberculous Mycobacteria (NTM)
Sep 1, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Sep 1, 2022 08:00AM Paratek Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 3, 2022 04:05PM Paratek Pharmaceuticals Announces Second Quarter 2022 Revenue of $29.6 Million
Aug 1, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jul 25, 2022 04:05PM Paratek Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 3, 2022
Jul 1, 2022 04:05PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jun 21, 2022 04:05PM Paratek Pharmaceuticals (PRTK) Granted FDA Fast Track Designation for NUZYRA
Jun 21, 2022 04:05PM Paratek Pharmaceuticals’ NUZYRA® Receives FDA Fast Track Designation for the Treatment of Pulmonary Nontuberculous Mycobacterial (NTM) Disease Caused by Mycobacterium Avium Complex (MAC) and Mycoba
Jun 1, 2022 04:15PM Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Jun 1, 2022 04:05PM Paratek Pharmaceuticals to Present at the Jefferies 2022 Healthcare Conference
May 16, 2022 04:05PM Paratek Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference
View Older Stories